N@N

Drug Middlemen Spared by Trump and Musk, for Now

The article from MSN discusses how drug middlemen, specifically pharmacy benefit managers (PBMs), have been largely spared from criticism by former President Donald Trump and Elon Musk, despite their significant role in the pharmaceutical supply chain. PBMs negotiate drug prices between manufacturers, pharmacies, and insurance companies, often influencing which drugs are covered by insurance plans and at what cost to patients. While Trump has frequently targeted pharmaceutical companies for high drug prices, he has not focused on PBMs, possibly due to their complex role in potentially reducing costs in some scenarios. Similarly, Elon Musk, who has criticized various sectors for inefficiency, has not publicly addressed the practices of PBMs. This lack of scrutiny comes at a time when there is increasing legislative and public interest in how PBMs operate, with some lawmakers pushing for reforms to increase transparency and reduce the influence these middlemen have on drug pricing and availability. However, no significant changes or direct actions against PBMs from Trump or Musk have been noted, leaving the industry relatively untouched by their usual critiques.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/politics/government/drug-middlemen-spared-by-trump-and-musk-for-now/ar-AA1wHbp7 ]